Gemelli Biotech IBS-Smart study finds lower diagnostic costs in patients with suspected IBS
Gemelli Biotech’s IBS-Smart and Trio-Smart were linked to lower captured diagnostic costs in a 219-patient IBS study, but causality remains unproven.
Gemelli Biotech’s IBS-Smart and Trio-Smart were linked to lower captured diagnostic costs in a 219-patient IBS study, but causality remains unproven.
Gut diagnostics need proof, not buzz. Gemelli Biotech’s DDW 2026 visibility could test whether IBS and SIBO care is ready for precision tools.